- £23.39m
- £17.18m
- £2.86m
RCS - Angle PLC - Agreement with Recursion Pharmaceuticals
AnnouncementREG - Angle PLC - Notice of Interim Results and Webcast
AnnouncementRCS - Angle PLC - Data supporting FDA approval published in Journal
AnnouncementRCS - Angle PLC - Independent Parsortix study
AnnouncementREG - Angle PLC - Standard form for notification of major holdings
AnnouncementREG - Angle PLC - Standard form for notification of major holdings
AnnouncementREG - Angle PLC - Result of 2024 Annual General Meeting
AnnouncementREG - AIM - AIM Notice - 24/06/2024
AnnouncementREG - Angle PLC - Result of open offer
AnnouncementREG - Angle PLC - Posting of 2023 Annual Report & Notice of the AGM
AnnouncementREG - AIM - AIM Notice - 11/06/2024
AnnouncementRCS - Angle PLC - Parsortix and assays being showcased at EACR 2024
AnnouncementREG - Angle PLC - Publication of Circular
AnnouncementREG - Angle PLC - Results of placing and subscription
AnnouncementREG - Angle PLC - Preliminary Results
AnnouncementREG - Angle PLC - Proposed Placing, Subscription and Open Offer
AnnouncementRCS - Angle PLC - Study of ovarian cancer CTCs using Parsortix
AnnouncementREG - Angle PLC - New commercial agreement with large pharma
AnnouncementREG - Angle PLC - New commercial agreement with AstraZeneca
Announcement